Effect of Shi-Zhen-An-Shen Herbal Formula Granule in the Treatment of Young People at Ultra-high Risk for Psychosis: a Pilot Study

Overview

Journal Front Psychiatry

Specialty Psychiatry

Date 2023 Jul 13

PMID 37441142

Authors

Hong Zhu

Yanzhe Ning

Sisi Zheng

Sitong Feng

Linrui Dong

Hongxiao Jia

Affiliations

Soon will be listed here.

Abstract

Introduction: To date, there is no conclusive evidence for early interventions on ultra-high risk (UHR) for psychosis. The Chinese herbal medicine is confirmed to be beneficial in improving psychiatric symptoms and cognitive impairments for schizophrenia patients. However, the effect of Chinese herbal medicine on treating UHR patients remains unknown.

Methods: Eighty UHR patients were recruited from the outpatient department. They were randomly assigned to receive either Shi-Zhen-An-Shen herbal formula granule (SZAS-HFG) combined with aripiprazole placebo or aripiprazole combined with SZAS-HFG placebo for a 12-week treatment. The psychiatric symptoms were assessed using the Structured Interview for Prodromal Syndromes (SIPS). The Trail Making Test part A (TMT-A), Brief Visuospatial Memory Test (BVMT), Hopkins Verbal Learning Test (HVLT), and Continuous Performance Test (CPT) were used to assess cognitive functions. we also employed the Global Assessment of Functioning (GAF) to evaluate social functioning. The linear mixed-effects models were performed to detect the difference in effectiveness between the two groups.

Results: After 12-week treatment, both groups showed significant effects of time on SIPS, TMT-A, HVLT, BVMT, and GAF. There was a significant effect of group only on CPT. Moreover, we also found a significant interaction effect on GAF.

Conclusion: SZAS-HFG can effectively alleviate psychosis symptoms, and improve cognitive impairments and overall functioning as well as aripiprazole. Chinese Clinical Trial Registry, ChiCTR-IOR-17013513.

Citing Articles

Ziprasidone population pharmacokinetics and co-medication effects in Chinese patients.

Bao S, Yang S, Hua Z, Li J, Zang Y, Li X Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(12):9811-9821.

PMID: 38918237 DOI: 10.1007/s00210-024-03244-y.

References

Liu X, Feng S, Feng Z, Ma C, He Y, Li X . Protective Effects of Shi-Zhen-An-Shen Decoction on the Cognitive Impairment in MK801-Induced Schizophrenia Model. J Integr Neurosci. 2022; 21(6):164. DOI: 10.31083/j.jin2106164. View

Yung A, McGorry P . The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996; 30(5):587-99. DOI: 10.3109/00048679609062654. View

McGlashan T, Zipursky R, Perkins D, Addington J, Miller T, Woods S . Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 2006; 163(5):790-9. DOI: 10.1176/ajp.2006.163.5.790. View

Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F . The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2012; 70(1):107-20. PMC: 4356506. DOI: 10.1001/jamapsychiatry.2013.269. View

Yung A, Phillips L, Nelson B, Francey S, PanYuen H, Simmons M . Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry. 2010; 72(4):430-40. DOI: 10.4088/JCP.08m04979ora. View

Zhang T, Li H, Woodberry K, Seidman L, Zheng L, Li H . Prodromal psychosis detection in a counseling center population in China: an epidemiological and clinical study. Schizophr Res. 2014; 152(2-3):391-9. PMC: 4441955. DOI: 10.1016/j.schres.2013.11.039. View

Wieland L, Santesso N . Summary of a Cochrane review: Wendan decoction traditional Chinese medicine for schizophrenia. Eur J Integr Med. 2017; 15:81-82. PMC: 5649251. DOI: 10.1016/j.eujim.2017.09.009. View

Cropley V, Lin A, Nelson B, L E P Reniers R, Yung A, Bartholomeusz C . Baseline grey matter volume of non-transitioned "ultra high risk" for psychosis individuals with and without attenuated psychotic symptoms at long-term follow-up. Schizophr Res. 2015; 173(3):152-158. DOI: 10.1016/j.schres.2015.05.014. View

Nieman D, McGorry P . Detection and treatment of at-risk mental state for developing a first psychosis: making up the balance. Lancet Psychiatry. 2015; 2(9):825-34. DOI: 10.1016/S2215-0366(15)00221-7. View

10.

Ma C, Wu Y, Liu X, He Y, Jia Y, Chen P . Shi-Zhen-An-Shen Decoction, a Herbal Medicine That Reverses Cuprizone-Induced Demyelination and Behavioral Deficits in Mice Independent of the Neuregulin-1 Pathway. Neural Plast. 2021; 2021:8812362. PMC: 7932787. DOI: 10.1155/2021/8812362. View

11.

McGorry P . Welcome to Early Intervention in Psychiatry. Early Interv Psychiatry. 2011; 1(1):1-2. DOI: 10.1111/j.1751-7893.2007.00019.x. View

12.

Miller T, McGlashan T, Rosen J, Cadenhead K, Cannon T, Ventura J . Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull. 2004; 29(4):703-15. DOI: 10.1093/oxfordjournals.schbul.a007040. View

13.

Shaner A, Miller G, Mintz J . Schizophrenia as one extreme of a sexually selected fitness indicator. Schizophr Res. 2004; 70(1):101-9. DOI: 10.1016/j.schres.2003.09.014. View

14.

McGorry P, Hickie I, Yung A, Pantelis C, Jackson H . Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry. 2006; 40(8):616-22. DOI: 10.1080/j.1440-1614.2006.01860.x. View

15.

Berger G, Wood S, Ross M, Hamer C, Wellard R, Pell G . Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr Pharm Des. 2012; 18(4):570-5. DOI: 10.2174/138161212799316163. View

16.

Shi X, Fan F, Liu H, Ai Y, Liu Q, Jiao Y . Traditional Chinese Medicine Decoction Combined With Antipsychotic for Chronic Schizophrenia Treatment: A Systematic Review and Meta-analysis. Front Pharmacol. 2021; 11:616088. PMC: 7942273. DOI: 10.3389/fphar.2020.616088. View

17.

Schafer M, Klier C, Papageorgiou K, Friedrich M, Amminger G . [Early detection of psychotic disorders]. Neuropsychiatr. 2007; 21(1):37-44. View

18.

Deng H, Adams C . Traditional Chinese medicine for schizophrenia: A survey of randomized trials. Asia Pac Psychiatry. 2016; 9(1). DOI: 10.1111/appy.12265. View

19.

Marshall M, Rathbone J . Early intervention for psychosis. Cochrane Database Syst Rev. 2011; (6):CD004718. PMC: 4163966. DOI: 10.1002/14651858.CD004718.pub3. View

20.

McGorry P, Nelson B, Markulev C, Yuen H, Schafer M, Mossaheb N . Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial. JAMA Psychiatry. 2016; 74(1):19-27. DOI: 10.1001/jamapsychiatry.2016.2902. View